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Current guidelines define that pre-ICT primary site 
and nodal GTVs must be used for radiotherapy 
(RT) planning [1, 2]. Superiority of post-IC 
(induction chemotherapy) GTV (gross tumour
volume) over pre-IC GTV has not been still tested. 
We assessed the results of patients with 
locoregionally advanced head and neck squamous 
cell cancer (LASCCHN) treatment with IC 
following by chemoradiotherapy (CRT), using 
post-IC PET/CT images for IMRT planning [3, 4]. 
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47 patients with histologically confirmed LASCCHN (oro- and hypopharyngeal), all HPV negative, KPS 70% and signed written 
informed consent approved by the Lithuanian Bioethics Committee were included. The mean follow-up period was 36 (7-55) months. 
The mean PFS was 41.7 months (95% CI, 35.9-47.4), and mean OS was 41.6 months (95% CI, 36.3-46.9). The 3-years PFS and OS 
rate were 64% and 58%, respectively. The most common acute toxicities of grade 3-4 were febrile neutropenia 20%, leukopenia 
26.7%, mucositis 37.8%. Late toxicities of grade 3-4 were: dysphagia 2.2%, xerostomia 8.9% and osteoradionecrosis 2.1%. 
This study is promising for new target delineation strategies for LASCCHN after IC. Further analysis is required to ascertain the 
influence of FDG-PET/CT in target delineation and main clinical outcomes. This work was performed in the frame of the project 
“Development of 3D phantom for individualized dosimetry in radiotherapy (No. S-MIP-17-104) and was partly supported by the 
research grant of Lithuanian Research Council.
Conclusions: 
Two PET/CT were performed: one prior IC, and one 14 days after 3 cycles 
of IC (docetaxel 75mg/m2, cisplatin 75mg/m2 and 5-FU 750 mg/m2 day 1-
5). The gross tumour volume (GTV70) and gross nodal disease (GTV60) on 
the post-IC PET/CT scans were contoured by the radiation oncologist 
working in cooperation with an experienced nuclear medicine physician. 
The boost clinical target volume (CTV70) and nodal clinical target volume 
(CTV60) were obtained by GTV70 and GTV60 plus 5 mm respectively. 
The elective CTV (CTV50) included CTV70, CTV60 and bilateral elective 
lymphnodes. The margin of 3 mm was added for each CTV to create the 
planning target volumes (PTV70, PTV60 and PTV50). For high-risk 
volumes (PTV70 and PTV60) the prescribed doses were 70 Gy and 60 Gy
respectively, for PTV50 – 50 Gy.  CRT consisted of a chemotherapy with 
cisplatin (40 mg/m2 weekly) and RT (2 Gy once daily, 5 days a week). The 
primary end points were PFS. The secondary end points were OS and 
treatment toxicities. Acute toxicities were assessed using CTCAE v.4.0, late 
toxicities - using RTOG /EORTC criteria. 
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Reduction of target volume post induction chemotherapy using 
PET/CT in locally advanced HNSCC
Characteristics n (%)
Age (years)
Median (range)
Sex
Male
Female
Primary tumour site
Oropharynx
Hypopharynx
Tumour status (T)
T2
T3-4
Lymph node status (N)
N0-1
N2-3
Tumour stage
III
IV
Histological grade
G1-2
G3-4
55.5 (30-71)
45 (95.7%)
2 (4.3%)
30 (63.8%)
17 (36.2%)
26 (55.3%)
21 (44.7%)
14 (29.8%)
33 (70.2%)
12 (25.5%)
35 (74.5%)
7 (14.9%)
40 (85.1%)
Baseline patient and tumour characteristics
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